ELP-004 is a drug to treat rheumatoid arthritis by directly targeting the cells that cause the bone erosion instead immune components elevated in arthritis. ELP-004 is not immunosuppressive. ELP-004 is a small molecule that is easy and inexpensive to produce and is effective when administered orally.
Primary Application Area: Biotech, Pharma, Health
Technology Development Status: Prototype
Technology Readiness Level: TRL 4
Vetted Programs/Awards: We have a funded Small Business Technology Transfer grant from NIH (NIAMS) to develop this drug.
Organization Type: Early-stage Startup (Seed)
Showcase Booth #: M40, T40
GOVT/EXTERNAL FUNDING SOURCES
External Funding to Date: None other than NIH